Articles From: IMAX And AMC Theatres Sign 11-Theatre Deal; Brings AMC IMAX Footprint To 159 Theatres to ImmunoCellular Therapeutics Receives Positive Regulatory Feedback on ICT-107 Supporting Advancement to Registrational Phase III Testing in Newly Diagnosed Glioblastoma


Agreement with IMAX's Largest North American Exhibitor Includes 13-Year Lease Terms for New IMAX® Theatres at AMC Locations in Chicago, New York, Newark and Phoenix NEW YORK and LEAWOOD, Kan.
Sign-up for IMAX And AMC Theatres Sign 11-Theatre Deal; Brings AMC IMAX Footprint To 159 Theatres investment picks
2014/8/13
Deal Boosts Cinepolis' IMAX Footprint and Marks Exhibitor's First IMAX Screens in U.S. NEW YORK , Aug.
Sign-up for IMAX And Cinepolis Sign Three-Theatre Agreement In U.S. Which Expands Partnership To 25 Theatres In Eight Countries investment picks
2014/7/24
HIGHLIGHTS - Operating leverage drives approximately 15% growth in adjusted net income in the second quarter compared to Q2 2013, contributing to $21.3 million in cash flow from operations in the quarter - IMAX installs 30 new theaters across 13 countries in Q2, including 12 new theaters in China - Company signs deals for 24 theater systems in the second quarter, bringing backlog to 419 theaters NEW YORK , July 24, 2014 /PRNewswire/ -- IMAX Corporation (NYSE: IMAX; TSX: IMX) today reported second quarter 2014 revenues of $79.1 million , adjusted EBITDA as calculated in accordance with the Company's credit facility of $32.8 million , adjusted net income, after non-controlling interest, of $17.2 million , or $0.25 per diluted share, and reported net income, after non-controlling interest, of $13.3 million , or $0.19 per diluted share.
Sign-up for IMAX Corporation Reports Second Quarter 2014 Financial Results investment picks
IMAX Corporation to Announce Third-Quarter 2014 Financial Results and Host Conference Call Canada NewsWire NEW YORK , Oct.
Sign-up for IMAX Corporation to Announce Third-Quarter 2014 Financial Results and Host Conference Call investment picks
IMAX Corporation To Present At The Goldman Sachs 23rd Annual Communacopia Conference Canada NewsWire NEW YORK , Sept.
Sign-up for IMAX Corporation To Present At The Goldman Sachs 23rd Annual Communacopia Conference investment picks
The Young Law Firm (the “Firm”), a national shareholder litigation firm, is investigating potential claims concerning the proposed merger of Intermountain Community Bancorp (“Intermountain” or the “Company”) (NASDAQ: IMCB) to Columbia Banking System, Inc (“Columbia”). On July 23, 2014 the Company announced it had entered into a merger agreement with Columbia to merge Intermountain into Columbia in a stock and cash transaction valued at approximately $121.5 million or approximately $18.22 per share based on Columbia’s July 23, 2014 stock price.
Sign-up for IMCB Shareholder Alert: The Proposed Merger Of Intermountain Community Bancorp To Columbia Banking System, Inc Is Under Investigation By The Young Law Firm investment picks
2014/7/15
PLACERVILLE, CA , July 15, 2014 /PRNewswire/ - IMD Companies Inc (OTC PINK: ICBU) and Red Apple Pharm (OTC BB: CETC) ( Berlin A1KB22) announced today that they have completed an agreement for IMD Companies Inc., to be a preferred vendor to supply equipment to build out medical Marijuana Grow facilities throughout the Western United States.
Sign-up for IMD Companies Inc., forms Partnership with Red Apple Pharm to develop Medical Marijuana Grow Facilities throughout Western United States investment picks
TAMPA, FL , July 24, 2014 /PRNewswire/ - iMD Companies, Inc. (OTC:ICBU) iMD Companies is pleased to announce that a group of accredited investors has signed an agreement to invest up to $500,000.00 specifically targeted at growing the Company's core Gardening business.
Sign-up for iMD Companies Inc., Receives $500,000.00 Short Term Funding Commitment from Private Investment Group investment picks
SEATTLE and SOUTH SAN FRANCISCO, Calif., July 25, 2014 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ) announced today that the day after it began trading on the Nasdaq Global Market, Theravectys SA ("TVS") filed a lawsuit against the company repeating claims that it had made in a prior lawsuit which TVS had earlier voluntarily dismissed.
Sign-up for IMDZ Announces Filing of New Lawsuit by Theravectys SA investment picks
WINDERMERE, Fla.
Sign-up for iMedicor Signs Relationship with Florence-Darlington Technical College investment picks
Plantronics (NYSE:PLT), a pioneer in audio and wearable technology, today announced BackBeat PRO , wireless active noise-cancelling headphones with battery power to outlast your playlist.
Sign-up for Immerse Yourself in Uncompromising Audio with the New Plantronics BackBeat PRO Wireless Active Noise-Cancelling Headphones investment picks
Immersion Corporation (NASDAQ:IMMR), the leading developer and licensor of touch feedback technology, today announced that it has signed a new agreement with LG Electronics, Inc., one of the world’s largest providers of mobile devices.
Sign-up for Immersion and LG Sign License Agreement for Tactile Effects investment picks
Immersion Corporation (NASDAQ:IMMR), the leading developer and licensor of touch feedback technology, today announced that it has extended its license agreement with Samsung, for the use of TouchSense® and Integrator products in smartphones and other mobile devices, to the company’s printing solutions business unit.
Sign-up for Immersion Announces License with Samsung Printing Solutions investment picks
Immersion Corporation (NASDAQ:IMMR), the leading developer and licensor of touch feedback technology, today reported financial results for the second quarter ended June 30, 2014.
Sign-up for Immersion Corporation Reports Second Quarter 2014 Results investment picks
Immersion Corporation (NASDAQ:IMMR), the leading developer and licensor of touch feedback technology, today announced that the company has launched TouchSense ® Engage , its groundbreaking software solution for enhancing mobile video with tactile effects.
Sign-up for Immersion Launches Solution for Adding Haptics to Video and Ad Content investment picks
Immersion Corporation (NASDAQ: IMMR), the leading developer and licensor of touch feedback technology, announced today that Chief Financial Officer Paul Norris will present to the investment community at the Needham Interconnect Conference on Wednesday, August 6, 2014 at 10:00 am Eastern Time.
Sign-up for Immersion to Present at the Needham Interconnect Conference investment picks
Immersion Corporation (NASDAQ:IMMR), the leading developer and licensor of touch feedback technology, announced today that it will report financial results for the second quarter of fiscal 2014 on Thursday, July 31, 2014 after the close of market.
Sign-up for Immersion to Report Second Quarter 2014 Results and Host Quarterly Conference Call on July 31st investment picks
SEATTLE and SOUTH SAN FRANCISCO, Calif., Oct.
Sign-up for Immune Design Added to Russell 2000(R) Index investment picks
SEATTLE and SOUTH SAN FRANCISCO, Calif., July 29, 2014 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ) announced today the closing of its initial public offering of 5,000,000 shares, at a public offering price of $12.00 per share, resulting in aggregate gross proceeds of $60.0 million, before underwriting discounts, commissions and expenses.
Sign-up for Immune Design Announces Closing of Initial Public Offering investment picks
SEATTLE and SOUTH SAN FRANCISCO, Calif., July 24, 2014 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ) announced today the pricing of its initial public offering of 5,000,000 shares of its common stock at a price of $12.00 per share for an aggregate offering of $60.0 million, before underwriting discounts, commissions and expenses.
Sign-up for Immune Design Announces Pricing of Initial Public Offering investment picks
2014/9/18
Company Recently Initiated Phase II in Bullous Pemphigoid CAMBRIDGE, Mass.
Sign-up for Immune Pharmaceuticals Initiates Phase II Clinical Trial In Ulcerative Colitis investment picks
2014/9/8
Immune Pharmaceuticals Recently Uplisted to NASDAQ Capital Market CAMBRIDGE, Mass.
Sign-up for Immune Pharmaceuticals Presenting At The 16th Annual Rodman & Renshaw Global Investment Conference, September 10, 2014 investment picks
2014/8/7
Conference Call Today at 5:00 pm ET LOS ANGELES , Aug.
Sign-up for ImmunoCellular Therapeutics Announces Second Quarter 2014 Financial Results investment picks
2014/9/24
Ex-Vivo Manipulation of Autologous Hematopoietic Stem Cells Complements Dendritic Cell-based Vaccine Platform; Potential to Develop Single-Agent and Combination Immunotherapeutics LOS ANGELES , Sept.
Sign-up for ImmunoCellular Therapeutics Expands Cancer Immunotherapy Platform with Antigen-Specific T-cell Technology Licensed from Caltech investment picks
ICT-107 Phase II Update Selected for Oral Presentation at Society for Neuro-Oncology Meeting in November; ICT-121 and ICT-140 Programs on Track LOS ANGELES , Sept.
Sign-up for ImmunoCellular Therapeutics Receives Positive Regulatory Feedback on ICT-107 Supporting Advancement to Registrational Phase III Testing in Newly Diagnosed Glioblastoma investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: IMAX And AMC Theatres Sign 11-Theatre Deal; Brings AMC IMAX Footprint To 159 Theatres to ImmunoCellular Therapeutics Receives Positive Regulatory Feedback on ICT-107 Supporting Advancement to Registrational Phase III Testing in Newly Diagnosed Glioblastoma
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices